PBR6 ISAM: INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT.THE ITALIAN EXPERIENCE  by Attinà, G et al.
733Abstracts
total hip replacement (THR) separately. Efﬁcacy data were
extracted from published randomised controlled trials. Cost data
were derived from the literature and other published sources and
natural history data after VTE from observational studies. Costs
were expressed in 2003 Swiss Francs (CHF) and effects as life-
years gained (LYG). Deterministic sensitivity analysis was used
to assess the robustness of the model. RESULTS: In patients
undergoing HFS, the incremental cost-effectiveness ratio (ICER)
of extended fondaparninux prophylaxis versus a one-week
regimen was CHF 2920/LYG after 30 days, with cost-savings
reached after 5 years. In patients undergoing THR, the ICER of
extended fondaparninux prophylaxis versus a 1-week regimen
was CHF 21183/LYG after 30 days, with cost-savings reached
after 5 years. CCONCLUSIONS: Within the limitations of the
model, extended prophylaxis with fondaparinux is cost-effective
for the prevention VTE in major orthopaedic surgery in 
Switzerland.
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OBJECTIVES: ISAM, a multicenter, observational, retrospec-
tive, cross-sectional study, aimed at describing the anticoagula-
tion treatment monitoring on patients with chronic non-valvular
atrial ﬁbrillation (CNVAF), receiving Oral Anticoagulation
Therapy (OAT) for stroke prophylaxis, (follow-up Jan-Dec
2002); and estimating direct and indirect costs in the Italian
National Health System perspective. METHODS: Seven out of
8 Anti-Coagulation Clinics (ACC’s), selected to represent the
whole Italian territory, enrolled 23 randomized patients with
CNVAF. RESULTS: The total number of patients was 177 :102
males and 75 females (mean age 72 years); 90% with chronic
Atrial Fibrillation and 10% with paroxysmal; 77% subjects
received warfarin and 23% acenocumarol. Forty percent of all
tests required dosage changes and the mean interval between two
consecutive tests was 20 days. The quality of OAT monitoring,
according to Rosendaal’s analysis, was: 67.9% of time spent in
the range 2.0–3.0, 21% below and 10% above this range. Unit
costs, using National tariffs were: 5.16€ and 12.91€ for INR 
tests and visits respectively, retail price for drugs (warfarin:
0.0145€/mg; acenocumarol: 0.0095€/mg) and appropriate DRG
tariffs for admissions. Total cost per patient per year was 943€:
745€ direct costs and 198€ indirect ones. Medical costs, 525€,
included OAT drug (5%), INR tests (18%), monitoring visits
(44%) and admissions (33%); non-medical costs (transporta-
tion) amounted to 220€. CONCLUSIONS: Patients in ACC
management could obtain good level of INR control: Time in
Target Range (TTR) 67.9%. ISAM is a ﬁrst attempt to assess
cost of OAT monitoring in Italy, conﬁrming that AF is a growing
health problem, as well as a cause of health costs that includes
drugs, INR tests and monitoring visits, which are the most deter-
minant in the total costs. In addiction, indirect costs (productiv-
ity loss by patients or their caregivers) were 21% of total costs.
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OBJECTIVES: To evaluate the preferences of physicians and
pharmacists toward products used for replacement therapy.
METHODS: This study investigates preferences on hemophilia
care in 69 physicians and 58 pharmacists using conjoint analy-
sis, a technique for establishing the relative importance of dif-
ferent characteristics in the provision of a good or service.
Attributes and levels were: perceived viral safety (as that pro-
vided by highly puriﬁed double inactivation plasma derived
versus recombinant concentrates), risk of inhibitor development
(1/4, 1/6, 1/10 PUP’s), factor infusion frequency on prophylaxis
(thrice, twice, once a week), pharmaceutical dosage form
(lyophilized material or a ready-to-use solution), way of distrib-
ution (home, ofﬁce pharmacy, hospital) and price. RESULTS:
Excluding pharmaceutical dosage form for physicians and ofﬁce
pharmacy delivery for pharmacists, all attributes considered
tested important to respondents. Physicians showed a strong
preference toward both outcome variables (viral safety, risk of
development of inhibitors) and process variables (distribution,
infusion frequency) while pharmacists showed a strong prefer-
ence only for outcome variables and unexpectedly not toward
way of distribution. CONCLUSIONS: Our study is the ﬁrst to
apply conjoint analysis to establish preferences of physicians and
pharmacists in hemophilia replacement therapy. This study pro-
vided evidence of the usefulness of conjoint analysis in plan
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